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Abstract. The optimization of large-scale screening procedures of pathological specimens by genomic, proteomic and metabolic
methods has drastically increased the bioanalytical capability for swiftly identifying novel biomarkers of inherited disorders,
such as neuromuscular diseases. X-linked muscular dystrophy represents the most frequently inherited muscle disease and is
characterized by primary abnormalities in the membrane cytoskeletal protein dystrophin. Mass spectrometry-based proteomics
has been widely employed for the systematic analysis of dystrophin-deficient muscle tissues, using patient samples and animal
models of dystrophinopathy. Both, gel-based methods and label-free mass spectrometric techniques have been applied in compar-
ative analyses and established a large number of altered proteins that are associated with muscle contraction, energy metabolism,
ion homeostasis, cellular signaling, the cytoskeleton, the extracellular matrix and the cellular stress response. Although these new
indicators of muscular dystrophy have increased our general understanding of the molecular pathogenesis of dystrophinopathy,
their application as new diagnostic or prognostic biomarkers would require the undesirable usage of invasive methodology.
Hence, to reduce the need for diagnostic muscle biopsy procedures, more recent efforts have focused on the proteomic screening
of suitable body fluids, such as plasma, serum or urine, for the identification of changed concentration levels of muscle-derived
peptides, protein fragments or intact proteins. The occurrence of muscular dystrophy-related protein species in biofluids will
be extremely helpful for the future development of cost-effective and non-invasive diagnostic procedures. Novel biomarker
signatures of dystrophinopathies will be indispensible for the swift evaluation of innovative therapeutic approaches, such as
exon skipping, codon-read-through or stem cell therapy.
Keywords: Biomarker discovery, Duchenne muscular dystrophy, dystrophin, dystrophinopathy, mass spectrometry, muscle
pathology, neuromuscular disease, proteomics, skeletal muscle proteome
INTRODUCTION
Over the last decade, skeletal muscle proteomics
has developed into a new discipline within the field
of basic and applied myology [1]. Proteomics has
been applied to a wide range of muscle-related topics,
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including muscle development [2], muscle fibre type
specification [3, 4], the effects of various physical
exercise regimes [5–7], muscle recovery following
injury [8], gender dimorphism [9], myokine secre-
tion [10–12], chronic stimulation-induced fast-to-slow
muscle transitions [13], muscular hypertrophy [14],
unloading-related muscular atrophy [15, 16], the effect
of chronic hypoxia [17–19] and fibre wasting dur-
ing the natural process of skeletal muscle aging
[20–22]. In addition, proteomics was instrumental
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in the determination of key post-translational mod-
ifications in muscle proteins such as glycosylation
[23], phosphorylation [24], carbonylation [25], nitro-
sylation [26] and acetylation [27]. The systematic
proteomic screening of skeletal muscle pathologies has
included the analysis of patient biopsy material and
muscle preparations from established animal models
of muscle diseases, covering neuromuscular abnor-
malities such as drug-related muscle damage [28],
toxin-associated muscle alterations [29], denervation-
induced muscular atrophy [30, 31], motor neuron
diseases [32–34], limb-girdle muscular dystrophy
[35], hyper-excitability related myotonia [36], insulin
resistance and diabetes-associated muscle weakness
[37–39], obesity-related changes in muscle tissues
[40, 41], inclusion body myositis [42], autoimmune
myasthenia gravis [43], dysferlinopathy [44], myofib-
rillar myopathies [45–47], and post-mortem changes
in skeletal muscle [48]. In addition, the downstream
effects of dystrophin deficiency were studied by vari-
ous proteomic approaches [49].
Building on these extensive sources of informa-
tion, this review focuses specifically on the mass
spectrometry-based identification of novel proteomic
biomarkers of dystrophinopathies and their potential as
future diagnostic tools. Proteins are listed by functional
families including internal muscle-associated proteins
involved in the contraction-relaxation cycle, glycoly-
sis, mitochondrial metabolism, cellular signaling, ion
handling, the extracellular matrix, the cytoskeleton and
the cellular stress response, as well as muscle-derived
peptides, protein fragments and intact proteins that are
leaked or released into body fluids such as plasma,
serum or urine. The importance of proteomic biomark-
ers for the future development of superior diagnostic
procedures is discussed.
PROFILING OF MUSCLE-ASSOCIATED
AND MUSCLE-DERIVED PROTEINS
Skeletal muscle proteomics
High-resolution gel electrophoresis and/or liquid
chromatography have been routinely used to sepa-
rate various protein constellations from skeletal muscle
specimens. The identification of muscle proteins by
mass spectrometry has been carried out with both
labelling approaches and label-free analyses [50].
The systematic cataloguing of the highly dynamic
skeletal muscle proteome has established a list of sev-
eral thousand proteins and isoforms that are present
in greatly varying concentration ranges in voluntary
contractile tissues [4, 51–53]. Organelle proteomics
has established the subproteome of distinct muscle
fractions [54], such as the sarcolemma, the sarcoplas-
mic reticulum and mitochondria [55–57]. Recently,
several extensive reviews have summarised and crit-
ically examined the impact of large-scale proteomic
approaches for our general understanding of human
muscle biology [1], skeletal muscle differentiation and
aging [58], muscle plasticity and fibre heterogeneity
[59] and exercise-induced fibre adaptations [60, 61],
as well as the molecular composition of the contrac-
tile apparatus [62] and the dystrophin-glycoprotein
complex [63]. In addition, the technical challenges
and emerging techniques in muscle proteomics [50]
and key issues in proteomic biomarker discovery
in the field of neuromuscular disorders [64] have
been reviewed. These articles have outlined in detail
the most commonly employed methods for protein
separation and protein identification used in muscle
tissue proteomics and also contain detailed listings of
proteomic investigations with relevance to inherited
muscle diseases. Thus, for detailed background infor-
mation on proteomic strategies as specifically applied
to skeletal muscle biology, we would like to refer to
the above listed publications.
Skeletal muscle proteome complexity
Various technical limitations and biological issues
complicate the proteomic screening of crude muscle
extracts for the swift identification of new disease-
specific biomarkers. These issues are encountered
during almost all global analyses of protein con-
stellations in complex tissues and organs [65–67].
On the cellular level, skeletal muscles are highly
diverse in their composition and consist of the main
contractile fibres, which exist in a wide range of multi-
nucleated slow-oxidative, fast-oxidative-glycolytic,
fast-glycolytic or hybrid cell types [68], in conjunction
with satellite cell pools underneath the basal lamina,
distinct layers of connective tissue comprising of the
endomysium, perimysium and epimysium, a complex
network of capillaries, and motor neurons and their
specialized connection sites at the neuromuscular junc-
tion [64]. On the subcellular level, various muscle
proteins display a multi-compartmental localization
and a considerable dynamic in their cellular move-
ments and interaction patterns [54]. On the molecular
level, muscle tissues display a highly diverse number
of protein families with an exceptionally large variety
of isoforms, which exist in a wide dynamic range of
expression levels [4, 51–53].
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Technical limitations and biological issues in
muscle proteomics
In the case of technically straightforward catalogu-
ing studies of the muscle proteome [51, 53], the
exceptional sensitivity and analytical capability of
modern mass spectrometers enables the comprehen-
sive evaluation of heterogeneous tissue extracts for
the efficient identification of specific isoforms of even
low copy number proteins [69]. In contrast to shot-
gun proteomics, the extensive molecular and cellular
heterogeneity in contractile tissues presents a serious
analytical challenge in comparative pathobiochemical
studies. Muscle diseases are often related to com-
plex changes. For example, the progressive nature of
X-linked muscular dystrophy is associated with alter-
ations in the interstitial volume, a drastic increase in
connective tissue, elevated endomysial fat layers and
the infiltration of damaged fibres by cells that provide
the natural immune response. These additional changes
in an already highly heterogeneous cell mixture cer-
tainly complicate the interpretation of studies using
tissue proteomics. In addition, the preferential suscep-
tibility of certain fibre types to necrosis may result
in complex and unpredictable fiber type transitions
during different disease stages [70]. A potential prepar-
ative artifact is the occurrence of abundant blood-borne
proteins in skeletal muscle homogenates, such as
hemoglobin subunits, which depends heavily on the
appropriate usage of tissue perfusion prior to protein
extraction and large-scale protein separation.
These technicalproblemsandbiologicalmattersmay
genuinely complicate the proper interpretation of find-
ings from comparative tissue proteomics and make it
difficult to distinguish between protein changes due
to general tissue damage, adaptive processes during
regeneration cycles and highly disease-specific alter-
ations downstream from the primary genetic insult.
In the case of analyzing needle biopsy material from
Duchenne patients, an additional issue is the fact that
a tissue sample from a single biopsy might not be fully
representative of the overall pathology in whole muscle
[71]. Usually a wide heterogeneity of muscle defects
exists within the neuromuscular system in the same
patient, limiting thevalidityofbiomedicaldata received
from a single biopsy. This may seriously complicate the
extrapolation of proteomic biomarker findings in the
case of monitoring therapeutic interventions.
Serum markers of muscle damage
In the past, an array of muscle-derived protein mark-
ers has been used for diagnostic purposes. However,
many of these biomarkers do not exhibit a high degree
of specificity and/or consistent concentration changes
in the acute or chronic disease stage, which restricts
their usefulness for accurate diagnosis, proper moni-
toring of dystrophic progression and clinical outcome
measures. General serum markers of muscle injury
or cellular damage include creatine kinase, carbonic
anhydrase isoform CA3, troponin subunit TnI, myosin
light chain MLC1, fatty acid binding protein FABP3,
myoglobin, aspartate amino transferase, alanine amino
transferase, hydroxybutyrate dehydrogenase, adeny-
late kinase, aldolase, pyruvate kinase, enolase and
lactate dehydrogenase [64, 72, 73]. The graph in Fig. 1
shows the normal range of human plasma-associated
proteins. It has been estimated that the concentration
range of plasma proteins ranges from ρg/ml-values at
the low end to mg/ml-values at the high end [74].
General markers of tissue leakage, including serum
proteins indicative of muscle damage, are marked in
Fig. 2. Their elevated appearance in serum or plasma
samples is a general sign of impaired fibre integrity. It
is important to note that plasma and serum biochem-
istry depends considerably on the reproducibility of
the sampling method, which is especially crucial in
the case of comparative studies.
Proteomic complexity of body fluids
Although plasma, serum, urine, saliva and other
biofluids are ideal sources for the swift discovery of
new disease markers, as well as present the preferred
minimally invasive specimens to test normal individu-
als, at-risk groups and patients, the potential problem
with the wide dynamic protein expression range is a
serious analytical issue with most body fluids [75].
This is especially apparent in the case of the serum
and plasma proteome and neither liquid chromatog-
raphy nor high-resolution gel electrophoretic methods
are capable of separating the entire spectrum of pro-
teins within a complex biological mixture [76]. The
extremely wide dynamic range of protein concentra-
tions present in human plasma, as outlined in Figs. 1
and 2, represents a major obstacle. Low-abundance
proteins such as many cytokines are present at a
concentration in the ρg/ml range, while albumin is
present at concentrations in the region of 30–45 mg/ml
[77]. This huge difference in concentrations repre-
sents at least twelve orders of magnitude with the
potential to be even greater as some biomolecules are
present at concentrations lower than many cytokines
[78]. In addition, many low-abundance components
bind to highly abundant proteins, such as albumin,
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Fig. 1. Graphical presentation of the dynamic range of high-abundance proteins in the human plasma proteome. Shown is the average concen-
tration range of high-abundance plasma proteins representing classical plasma-associated proteins, such as albumin, various immunoglobulins,
transferrin, ferritin, plasminogen and numerous complement proteins.
thereby masking their presence. This adds a layer
of complexity to their detection and quantification,
which should be properly considered when using pre-
fractionation approaches, such as immuno-depletion
protocols [79, 80].
A major advantage of body fluids is the ability
to take serial samples to monitor disease burden or
response to therapeutic agents based on altering levels
of suitable protein biomarkers. Biological material
assayed for biomarker discovery can also originate
from proximal fluids, which are defined as biofluids
in close or direct contact with the site of disease.
In contrast to serum or plasma, it is very likely that
these biomarker-rich reservoirs will facilitate the
discovery of disease-related biomarkers. Depending
on the specific disorder, suitable proximal biofluids
may include cerebrospinal fluid, broncho-alveolar
lavage fluid, saliva, urine, cerumen, tears and various
gastrointestinal fluids such as bile, pancreatic juice and
gastric juice [81–83]. For example, levels of HIP/PAP-
I (hepatocarcinoma-intestine-pancreas/pancreatitis-
associated-protein-I) were found to be approximately
1000-fold higher in pancreatic juice as compared
to serum from patients diagnosed with pancreatic
adenocarcinoma [84]. However, mirroring difficul-
ties associated with investigating serum or plasma,
proximal biofluids also have a wide dynamic range
of protein abundance levels, with cerebrospinal
fluid having up to twelve orders of magnitude [85].
To help assist the detection of low-abundance and
disease-specific biomarkers, a number of fractionation
and enrichment strategies are available to provide a
standardised method to process biofluid specimens
including immuno-depletion, combinatorial hexapep-
tide ligand libraries and nanoparticle harvesting
approaches.
Protein enrichment strategies in biofluid
proteomics
The extremely high concentration of a few pro-
teins in serum or plasma seriously interferes with the
identification of low copy number proteins. There-
fore the high concentration of proteins such as
albumin, transferrin, fibrinogen, haptoglobin, anti-
trypsin, transthyretin and various immunoglobulins
P. Dowling et al. / Proteomics of Dystrophinopathies 19
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Fig. 2. Graphical presentation of the dynamic range of low-abundance proteins in the human plasma proteome. Shown is the average concentration
range of general plasma-associated protein markers of tissue leakage and low-abundance plasma proteins. The average, normal abundance of
typical muscle-derived proteins, such as aldolase, myoglobin, carbonic anhydrase, fatty acid binding protein, creatine kinase and troponin
subunits, is marked. Drastically increased levels of these proteins in serum or plasma samples are indicative of general muscle damage and
disintegration of fibre integrity.
necessitates often pre-fractionation steps in order to
be able to detect low-abundance proteins in serum
samples [79, 80, 86]. Immuno-depletion of biofluid
specimens for the removal of highly abundant pro-
teins is a practical and reproducible solution. Typically,
selected proteins are removed using immuno-depletion
columns containing antibodies against the hyper-
abundant proteins such as albumin, IgG, IgA, IgM,
fibrinogen, transferrin and haptoglobin. Removal of
high-abundance proteins and consequently the estab-
lishment of an enriched pool of low-abundance
proteins enable improved resolution and a compressed
dynamic range for biomarker discovery experiments
using label-free shotgun profiling with LC-MS/MS
analysis, as well as two-dimensional gel-based tech-
niques. Immuno-depletion of clinical samples has
facilitated the discovery of many candidate biomark-
ers and is now routinely used as a robust strategy
to help overcome some of the problems associated
with dynamic range [87, 88]. However, immuno-
depletion is not without some drawbacks. One of
the most significant problems is the co-depletion of
many low-abundance proteins during the processing
of samples as a consequence of non-specific binding
to antibodies or through their interactions with highly
abundant proteins such as albumin. This is known as
the carrier-and-cargo effect. Importantly, Yadav et al.
[89] identified 101 proteins with high confidence in the
bound fractions from three plasma samples depleted
using each of the three multi-affinity removal system
MARS cartridges, e.g. Hu-6, Hu-14 and Proteoprep
20. Such results strongly suggest it may be prudent to
analyse both high and low abundant fractions to maxi-
mize the overall detection rate and quantification of as
many plasma-associated proteins as possible.
Hexapeptide libraries, such as ProteoMiner™ pro-
tein enrichment technology, can substantially increase
the sensitivity of shotgun proteomic analyses of
complex biofluid samples [90, 91]. Dynamic range
compression is a result of high abundant proteins
quickly saturating their specific ligands while medium-
and low-abundant proteins continue to bind to their
20 P. Dowling et al. / Proteomics of Dystrophinopathies
ligands, resulting in a significant dilution of high-
abundance proteins while low-abundance molecules
are concentrated. The ProteoMiner™ technology is
based on a combinatorial library of hexapeptides bound
to a chromatographic support. The vast ligand diversity
based on 64 million unique beads generated offers in
theory a ligand for every protein present in the starting
material. Currently, hexapeptide libraries have been
mostly used to increase proteomic detection in biofluid
samples such as serum and plasma, although Candiano
and co-workers [92] reported that at least 3,300 pro-
tein spots could be visualized in a two-dimensional
gel map from urine using a modified ProteoMiner™
enrichment approach.
Degradation of protein biomarkers can occur imme-
diately following the collection of biofluids as a result
of endogenous or exogenous proteinase activity. To
overcome this issue, nanoparticles or nanotraps are
able to concentrate and protect sensitive protein pop-
ulations. This approach uses a combination of size
exclusion and affinity capture methodology to enrich
for low-molecular-mass proteins [93, 94]. Both the size
exclusion and affinity capture components of the nan-
otraps are adjustable, therefore allowing researchers to
screen their clinical samples using a panel of molec-
ular baits to capture many disease-related proteins
present in the starting material. The suitability of this
technology is exemplified by a recent study with poly-
nanoparticles that reliably measured a low-abundance
protein analyte, the human growth hormone HGH
in urine [95]. This demonstrates how the match of
specific bait chemistry can be exploited to capture a
certain analyte. Traditional fractionation techniques
are also very effective at helping to increase the cover-
age of biofluid proteomes, including chromatography
approaches such as cation exchange, anion exchange,
one-dimensional polyacrylamide gel electrophoresis
and ZOOM® isoelectric focusing pre-fractionation
procedures [96–98]. Indeed, combinations of two or
more fractionation techniques have been employed by
some groups to generate many fractions, helping to
reduce sample complexity and enhance the ability to
identify low concentration biomolecules [99, 100].
PROTEOMIC ANALYSIS OF MUSCULAR
DYSTROPHY
Proteomic profiling of dystrophin and dystrophic
muscle tissues
The primary deficiency in the membrane cytoskele-
tal protein dystrophin is the underlying cause of
X-linked muscular dystrophy [101]. In normal mus-
cle, dystrophin forms a large complex with several
sarcolemmal proteins, including dystroglycans, sarco-
glycans, dystrobrevins, syntrophins and sarcospan
[102–104]. Figure 3 summarizes the proteins linked to
dystrophin at the interface between the subsarcolem-
mal cytoskeleton and the basal lamina and also outlines
the relationship of the dystrophin-glycoprotein com-
plex to other surface networks based on integrins
and spectrin located in the plasmalemma, as well as
utrophin at the neuromuscular junction [105, 106]. In
addition, major contractile and regulatory proteins of
the actomyosin apparatus, elements of intermediate
filaments and the lamin-associated nuclear mem-
brane complex are listed. Since direct or indirect
connections exist between the various extracellular,
sarcolemmal, cytoskeletal and contractile protein fam-
ilies, the absence of dystrophin and severe reduction
in dystrophin-associated glycoproteins may also affect
other components of the cytoskeleton, the contractile
apparatus or the extracellular matrix [107, 108]. Thus,
the leakage or release of proteins, protein fragments or
peptides belonging to these cytoskeletal or contractile
protein networks may be exploitable as muscle-derived
biomarkers of muscular dystrophy. A large number of
candidate proteins that are potentially altered in dys-
trophinopathies are listed in Fig. 3.
Mass spectrometry-based proteomics has been
widely applied to studying isolated components of
the dystrophin-glycoprotein complex [109–112] and
dystrophic muscle samples and biofluids. This has
included established animal models of muscular dys-
trophy [113–117] and patient specimens. Global
changes in muscle-associated proteins were deter-
mined using serum samples from the mdx mouse
[118, 119] and Duchenne patients [120–122], the
secretome of mdx myotubes [123], Duchenne mus-
cle biopsies [124], the cytosolic mdx muscle fraction
[125, 126], microsomes from mdx leg muscle [127],
crude mdx hind limb muscle extracts [128], individ-
ual mdx leg muscles including gastrocnemius, tibialis
anterior, extensor digitorum longus, soleus, flexor dig-
itorum brevis and interosseus muscles [129–132],
mildly affected mdx extraocular muscles [133, 134],
the severely dystrophic mdx diaphragm [134–139], the
mdx heart [140–142] and skeletal muscle extracts from
the grmd dog [143].
Although the primary insult causing a disease-
altered state in muscular dystrophy is the loss in
the dystrophin isoform Dp427 [101], assaying full-
length dystrophin is not necessarily the most suitable
biomarker test. The reason for this is the fact that
P. Dowling et al. / Proteomics of Dystrophinopathies 21
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Fig. 4. Summary of the routine proteomic workflow for the swift identification of new dystrophinopathy-related biomarker candidates. Suitable
biomarkers may be present in muscle fibres, muscle-associated but non-contractile tissues, non-muscle tissues or biofluids.
the primary abnormality in this essential membrane
cytoskeletal protein may trigger irreversible changes
in certain pathways and cellular signaling mechanisms
during the impaired development of dystrophin-
deficient fibres. Therefore, the successful restoration
of dystrophin in muscle fibres may not counter-act all
dystrophy-related abnormalities. This might include
the pathobiochemical consequences of progressive
fibre degeneration, extensive fibrotic scaring and the
extensive fatty tissue accumulation in dystrophic mus-
cles. However, even if dystrophin substitution by
pharmacological interventions or gene therapy does
not reverse all secondary changes [144–146], alter-
ations in the concentration of the Dp427 isoform
could be employed as a pharmacodynamic biomarker
that documents the successful reestablishment of the
primary abnormality in dystrophinopathy [147]. Addi-
tional tests are then needed to evaluate the clinical value
of therapeutic interventions, such as motor assess-
ment, general physical examinations, histological tests
and magnetic resonance imaging, as well as routine
protein marker assays of downstream effects. This
makes the identification of novel and reliable protein
biomarkers an urgent task of muscle proteomics and
warrants detailed investigations into proteome-wide
changes in muscular dystrophy. Figure 4 summa-
rizes the proteomic workflow for the identification
of novel dystrophinopathy-specific biomarker candi-
dates present in dystrophin-deficient muscle fibres,
non-muscle tissues or suitable body fluids.
Contractile and regulatory proteins of the
actomyosin apparatus
The proteomic screening of dystrophic muscle sam-
ples has revealed an altered concentration of the main
contractile and regulatory proteins of the actomyosin
apparatus. This includes myosin heavy chains, myosin
light chains, troponin, tropomyosin and actin, as well
as auxiliary proteins such as myosin binding protein,
myozenin, myomesin and -actinin [126, 129–132,
134–139, 143]. The gel electrophoretic analysis of the
cytosolic fraction of mdx hind limb muscle revealed
changes in myosin light chain MLC2 and tropomyosin
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[126], in conjunction with the drastic decrease in
adenylate kinase isoform AK1 [125]. While moder-
ate decreases in -actinin, fast myosin binding protein
MBP-C, -actin and myosin heavy chains MHC IIx
and MHCIIb were described to occur during the acute
phase of dystrophin-deficiency in mdx gastrocnemius
muscle as determined by 2D-DIGE analysis [129],
SILAC (stable isotope labeling by amino acids in cell
culture) proteomics showed slight decreases in various
myosin heavy chains, -actin and /-tropomyosin
[132]. Several other leg muscles exhibiting segmen-
tal necrosis were studied at a more advanced stage of
muscular dystrophy. Proteomics revealed alterations
in troponin TnC, myosin binding protein MBP-C
and myosin light chains MCL2 and MLC3 in soleus
muscle, troponin TnT and myosin heavy chain in
extensor digitorum longus muscle, troponin TnI and
/-tropomyosin in flexor digitorum brevis muscle
and troponin TnI in interosseus muscle [131], as
well as decreased -tropomyosin levels in aged mdx
tibialis anterior muscle [130]. Moderate differential
expression levels were established for tropomyosin,
myosin light chains MLC1, MLC2 and MLC3, various
myosin heavy chains, myosin binding protein MBP-
H, myotilin and myomesin in the dystrophic grmd dog
model of Duchenne muscular dystrophy [143].
The severely dystrophic mdx diaphragm showed
changes in various myosin heavy and light chains,
actin, troponins and actinin [134, 136–138]. Aged
mdx diaphragm muscle, which is characterized by
a drastic increase in collagen [138], exhibited dif-
ferential expression patterns of myosin light chains,
tropomyosin, troponins, actin and nebulin [139].
Interestingly, the myosin light chain isoform MLC1
was identified in secreted LAMP1-associated vesi-
cles [123], as described in below section on released
biomarkers in biofluids. In contrast to relatively moder-
ate and differential effects of dystrophin deficiency on
skeletal muscles, the cardiac proteome showed unilat-
eral decreases of many contractile proteins in muscular
dystrophy-associated cardiomyopathy [141, 142]. The
reduced abundance is especially striking for cardiac
myosin light chain MLC2, as revealed by fluores-
cence 2D-DIGE analysis [141]. However, despite the
many observed proteomic changes described in this
section, it is currently difficult to establish alterations
in a specific contractile protein as a suitable biomarker
assay for dystrophinopathies. The high abundance
and dynamic expression range of myosins and other
contractile proteins complicate the development of
sensitive tests for potential internal muscle markers.
Probably, a panel of proteins belonging to the acto-
myosin complex and its auxiliary structures would be
more appropriate for evaluating complex dystrophy-
related changes in the contractile apparatus.
Enzymes of energy metabolism
The continuous provision of energy is essential
for muscular activity making both the coordination
and maintenance of anaerobic and aerobic bioen-
ergetic pathways critical issues in contractile fibres
[148, 149]. Glycolytic enzymes and the mitochon-
drial subproteome make up a considerable part of the
muscle protein constellation [4, 51–53]. Mitochon-
drial proteins account for approximately 20% of the
skeletal muscle proteome [51] and the 10 glycolytic
enzymes represent the most abundant proteins of the
diffusible muscle fraction [150]. In general, muscle
wasting is closely associated with alterations in bioen-
ergetic provision and reflected by a variety of changes
in glycolysis [151] and oxidative phosphorylation
[152]. In dystrophinopathy, an impaired mitochondrial
metabolism appears to be based on the pathophysio-
logical uncoupling of oxidative phosphorylation and
a considerable reduction in maximal ATP synthesis
capacity [153]. This mitochondrial inefficiency and
resulting decreased intramuscular ATP levels might be
directly linked to a disrupted sub-sarcolemmal local-
ization of mitochondria due to dystrophin deficiency
in the actin membrane cytoskeleton [154].
Besides alterations in the localization and regulation
of bioenergetic organelles and shifts in the concen-
tration and/or isoform expression levels of metabolic
enzymes, the abundance and availability of metabo-
lite transporters and binding proteins may represent
limiting factors of bioenergetic pathways. Therefore
the transportation of glucose, amino acids, nucleotides,
fatty acids and oxygen on the one hand and the effi-
cient removal of waste products and CO2 on the other
hand play an essential role in muscle metabolism [148].
Dystrophy-related changes in metabolite transporta-
tion or removal have been reported to occur on the level
of myoglobin, fatty acid binding protein FABP3 and
carbonic anhydrase CA3. While aged mdx diaphragm
muscle has drastically lowered levels of fatty acid
binding protein and myoglobin [139], the aged mdx
tibialis anterior muscle showed high concentrations
of carbonic anhydrase [130]. This indicates impaired
utilization of fatty acids for oxidative metabolism in
severely dystrophic fibres and apparently an additional
need to remove excess CO2 from dystrophic mus-
cles. Muscle proteins involved in lipid metabolism,
mitochondrial bioenergetics, glycogen storage, glycol-
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ysis, gluconeogenesis and nucleotide metabolism have
shown a generally perturbed expression pattern, but
no clear unilateral shifts between anaerobic and aer-
obic metabolism are evident. However, since many
muscle proteins are probably multi-functional, it is
difficult to interpret individual changes within bioen-
ergetic pathways and their implications for overall
metabolic changes during muscle wasting.
Mitochondrial and glycolytic enzymes were
shown to display both increased and decreased
concentration levels in dystrophic muscles. Inter-
estingly, the enzyme aldolase has been shown to be
reduced in almost all subtypes of skeletal muscles
in dystrophic mouse or dog models of Duchenne
muscular dystrophy [129, 131, 134, 136, 137, 143].
During glycolysis, an aldolase-mediated reversible
reaction brakes down fructose-1,6-biphosphate into
glyceraldehyde-3-phosphate and dihydroxyacetone
phosphate [151]. The gluconeogenic enzyme fructose-
1,6-biphosphatase appears to form complexes with
aldolase in conjunction with -actinin on both sides
of the Z-line of muscle fibres [155]. This physical
linkage between key enzymes of glycolysis and
gluconeogenesis probably enables efficient substrate
channeling between these metabolic enzymes [156].
The decrease in aldolase in dystrophic muscle was
reversed after experimental exon-skipping therapy,
suggesting this glycolytic enzyme as a potential
internal muscle marker of metabolic adaptations in
muscular dystrophy [137]. The mitochondrial enzyme
isocitrate dehydrogenase exhibits also a significantly
reduced expression in dystrophic mdx diaphragm and
gastrocnemius muscle [132, 136] and exon-skipping
intervention counter-acts the loss in this critical
protein of the citric acid cycle [137]. Thus, both key
enzymes of the sarcoplasmic fraction and the mito-
chondrial matrix may be useful as pharmacodynamic
biomarkers in future gene therapy trials.
Numerous proteomic studies have convincingly
shown alterations in the nucleotide metabolism of
dystrophic muscles. The AK1 isoform of adenylate
kinase and mitochondrial creatine kinase are reduced
in dystrophic skeletal and cardiac muscles [125, 126,
135–137, 139, 141]. These proteomic findings were
verified by immunoblot analysis [125, 137]. Hence,
muscle nucleotide metabolism that involves the enzy-
matic activities of creatine kinase and adenylate kinase
seems to be altered in dystrophin-deficient fibres.
Experimental exon skipping therapy reversed the
reduction in both enzymes [137], establishing adeny-
late kinase AK1 and the mitochondrial form of creatine
kinase as potential muscle-associated biomarker can-
didates for the evaluation of therapy and disease
monitoring of progressive skeletal muscle wasting
and cardiomyopathic complications associated with
X-linked muscular dystrophy. In contrast to reduced
levels of enzymes of nucleotide metabolism, pro-
teins involved in iron metabolism were shown to be
increased in muscular dystrophy.
The comparative proteomic analysis of the contrac-
tile protein-depleted microsomal fraction from normal
versus dystrophic skeletal muscle revealed an increase
in ferritin and transferrin [127]. A moderate elevation
in transferrin was also show in the acute phase of dys-
trophin deficiency of young mdx muscle [129] and the
aging mdx heart exhibited drastic increases in iron-
regulatory proteins [142]. Ferritin is a ubiquitous intra-
cellular iron-binding protein involved in iron detoxifi-
cation and iron reserve by sequestering and releasing
iron in a highly regulated way. Transferrin serves as a
circulating protein, which delivers iron to tissue pro-
teins [157]. The elevated levels of iron-binding proteins
indicate disturbed iron homeostasis in dystrophin-
deficient fibres and might counter-act a potential iron
overload in muscular dystrophy. The fact that all mam-
malian cells require proper regulation of iron levels
for metabolic maintenance makes the concentration
of transferrin and ferritin crucial indicators of poten-
tial adaptations or impairments in iron absorption and
usage [158]. This might make iron-binding proteins
also suitable metabolic biomarker candidates for eval-
uating the status of X-linked muscular dystrophy.
Proteins involved in excitation-contraction
coupling and ion homeostasis
Excitation-contraction uncoupling and abnormal
Ca2+-fluxes through the dystrophin-deficient plas-
malemma, as well as impaired Ca2+-shuttling and
lowered Ca2+-buffering capacities in the cytosol and
the lumen of the sarcoplasmic reticulum are major
contributory factors of secondary alterations in mus-
cular dystrophy [159]. The calcium hypothesis of
muscular dystrophy assumes that abnormal calcium
homeostasis in mechanically stressed muscle cells
plays a key role in contractile weakness. Biochemical,
physiological and proteomic studies have confirmed
unbalanced ion cycling through the sarcolemma of dys-
trophic fibres and an impaired Ca2+-buffering capacity
of the terminal cisternae region of the sarcoplasmic
reticulum [128, 134, 135, 139, 160–164]. Abnormal
Ca2+-handling may contribute in a major fashion to
an enhanced level of muscle protein degradation [165,
166]. The normal movement of Ca2+-ions, which
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present one of the most critical second messenger
molecules in skeletal muscle, is maintained under
precise temporal and spatial control by the highly
regulated interactions between Ca2+-channels, Ca2+-
shuttle proteins, Ca2+-binding proteins, Ca2+-release
units, ion exchangers, Ca2+-pumping ATPases and
voltage-sensing receptors [167]. Disturbances of this
complex physiological system, which indirectly regu-
lates many metabolic and signaling mechanisms, may
result in severe fibre degeneration.
Dysregulation of excitation-contraction coupling
and muscle relaxation due to an anomalous intracel-
lular accumulation of Ca2+-ions and resulting chronic
Ca2+-overload is believed to cause disintegration of
sarcolemmal integrity by activating Ca2+-dependent
proteolytic processes [159, 166]. Micro-rupturing of
the dystrophin-deficient sarcolemma triggers a Ca2+-
related membrane re-sealing process that in turn
initiates the introduction of sarcolemmal patches con-
taining Ca2+-leak channels that provide an increased
influx of Ca2+-ions into the sarcoplasm of dys-
trophic fibres [164]. The comparative biochemical
and proteomic profiling of dystrophic muscle ver-
sus wild type has shown decreased levels of the
Ca2+-binding proteins parvalbumin, regucalcin, calse-
questrin, calsequestrin-like proteins and sarcalumenin
[128, 134, 135, 139, 162, 163]. The proteomic anal-
ysis of experimental exon skipping clearly showed
a reversal of the reduced levels of fast calsequestrin
following anti-sense treatment of the mdx diaphragm
muscle [137]. This makes changes in the concentration
of the cytosolic Ca2+-binding proteins parvalbumin
[139] and regucalcin [135], the luminal Ca2+-shuttle
protein sarcalumenin [162], the calsequestrin-like pro-
teins of high molecular mass named CLP1 to CLP5
[163] and the fast 63 kDa isoform of the luminal Ca2+-
binding protein calsequestrin [128, 134, 139] suitable
biomarker candidates for the monitoring of changes in
Ca2+-handling in dystrophic skeletal muscle.
Cytoskeletal and extracellular matrix proteins
The dystrophin-glycoprotein complex links the out-
side of the muscle fibre via the trans-sarcolemmal
dystroglycan sub-complex to the internal actin
cytoskeleton [104, 106, 108]. In both, mdx mouse
muscle and skeletal muscle biopsies from Duchenne
patients, the deficiency in dystrophin isoform Dp427
results in a drastic reduction in all dystrophin-
associated glycoproteins [102, 168, 169]. However, the
extracellular matrix protein laminin is not affected by
the primary abnormality in dystrophin [139] and the
cytoskeletal protein spectrin is also not altered in its
concentration in muscular dystrophy [168, 169]. This
makes laminin and spectrin suitable marker proteins
for equal loading controls in comparative biochemical
studies of dystrophic versus wild type skeletal muscle
specimens. However, in the dystrophic heart, laminin
was shown to be drastically reduced. Label-free mass
spectrometry revealed lower levels of laminin and
nidogen in the aged mdx heart and these findings were
confirmed by immunoblot analysis [142]. The dys-
trophic heart exhibits a variety of differences in its
secondary abnormalities as compared to dystrophin-
deficient skeletal muscle tissues [170], and possibly
the differing subcellular localization of the cardiac dys-
trophin complex might play a role in the drastic loss of
laminin. In the heart, dystrophin and its associated gly-
coproteins are located in both the sarcolemma and the
transverse tubules, while the skeletal muscle complex
is restricted to the sarcolemma and junctional folds
of the neuromuscular junction region. Thus, the mea-
surement of laminin levels might be a useful indicator
for the differential evaluation of muscular dystrophy
versus dystrophy-related cardiomyopathy.
Numerous proteomic studies indicate that the con-
centration of the extracellular matrix protein collagen
and the cytoskeletal proteins vimentin, desmin and
tubulin are increased in dystrophinopathies [129, 132,
134, 136, 138, 139]. Proteomic profiling and compar-
ative immunoblotting of the fibrotic status of the aged
mdx diaphragm revealed a drastic increase of the extra-
cellular matrix proteins collagen and dermatopontin
[138]. Although the natural aging process of the mus-
culature is associated with higher collagen levels [171],
senescent fibres lacking dystrophin exhibit a several
times elevated level of collagen [138]. The increased
density of the intermediate filament proteins vin-
culin and desmin and the main microtubule-forming
component tubulin indicate compensatory mecha-
nisms to counter-act the structural weakness of the
cytoskeletal network in dystrophic fibres [129, 132,
136]. Interestingly, desmin, vimentin and actin form
complexes with B-crystallin-like chaperones in con-
tractile tissues during prolonged periods of cellular
stress [172]. Small heat shock proteins appear to be
directly involved in the modulation of intermediate
filament assembly. Although vimentin appears to be
only transiently expressed during myotube matura-
tion [173], the concomitant increase in desmin and
the molecular chaperone cvHSP, as discussed in more
detail below, strongly suggests a stabilizing function
through increased levels of this cytoskeletal element.
The additional support of microtubules and interme-
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diate filaments might at least partially substitute for
the loss of dystrophin in the impaired actin membrane
cytoskeleton.
In addition, the dystrophic mdx heart is charac-
terized by a reduction in the protein lamin of the
nuclear envelope complex [142]. The reduced presence
of lamin may drastically weaken the linkage between
the lamin network and its associated proteins nesprin,
SUN1, SUN2 and plectin at the interface between mus-
cle nuclei and the cytoskeleton [174]. With respect
to biomarker discovery for dystrophinopathies, the
proteomic identification of altered concentration lev-
els in distinct cytoskeletal proteins suggests desmin,
vimentin, tubulin and lamin as potential candidates for
developing diagnostic tests for the differential analysis
of muscular dystrophy.
Molecular chaperones
During both normal contractile activities and patho-
logical conditions, considerable cellular stress is
exerted on the neuromuscular system. Therefore, the
continued preservation of muscle proteostasis is at
the core of protecting and adapting contractile tis-
sues. This includes on the one hand the maintenance
of correct protein folding, efficient protein transporta-
tion and appropriate protein complex arrangements to
provide the structural basis for diverse muscle func-
tions, and on the other hand the effective removal
of misfolded proteins during extended periods of
pathological adaptations or cellular stress [175]. In
skeletal muscle, various molecular chaperones are
involved in protein stabilization by supporting the cor-
rect functional fold of peptide domains and eliminate
non-functional protein aggregations [176]. Besides
protein disulfide isomerase, peptidyl prolyl isomerase,
calreticulin and calnexin, a large number of heat shock
proteins (HSP) are involved in the cellular stress
response [177]. Muscle-specific expression was shown
for low-molecular mass HSP molecules (HSPB), such
as the B-crystallin like cardiovascular HSP (HSPB7,
cvHSP) [178]. HSPs with higher molecular masses
are represented by HSP40 (DNAJ), HSP60 (HSPD),
HSP70 (HSPA) and its co-chaperones, HSP90 (HSPC)
and HSP110 [176].
Pathobiochemical studies of dystrophic muscles
have demonstrated an elevated concentration of HSP65
and HSP72 in hyper-contracted fibres from Duchenne
patients [179] and increases in HSP70 and HSP90 in
tissue extracts from Duchenne muscle samples [180].
The experimental iron deprivation of mdx muscle trig-
gered a selective decrease in the over-expression of
HSP70, suggesting that the iron-associated generation
of hydroxyl radicals may be linked to the severity of
muscle necrosis and possibly modify the cellular stress
response in dystrophinopathies [181]. The crucial role
of HSPs in the molecular pathogenesis of muscular
dystrophy is illustrated by the fact that exposure to the
experimental drug BGP-15, which represents a phar-
macological inducer of HSP72, clearly improves mus-
cle structure and contractile strength in dystrophic mdx
and dko mice [182]. Since the up-regulation of HSP72
acts via the functional restoration of the sarcoplasmic
reticulum Ca2+-ATPase [182] and transgenic over-
expression of this enzyme has been shown to attenuate
dystrophic features in mdx fibres [183], most likely the
restoration of a low cytosolic Ca2+-concentration and
reversal of excess sarcolemmal Ca2+-influx is crucial
in preventing muscle degeneration. Thus, molecular
chaperones like HSP72 are essential factors for the
cyto-protection of stressed fibres [182].
Proteomics has identified drastic changes in the
expression of cvHSP (HSPB7),BC (HSPB5), HSP70
(HSPA) and HSP90 (HSPC) in dystrophic muscles
[126, 127, 129, 134, 136, 139], which qualifies some
molecular chaperones as potential biomarkers of skele-
tal muscle degeneration [184]. In stressed muscle
fibres, a highly complex system of protective path-
ways is concerned with the continuous maintenance
of contractile and metabolic protein functions. Mus-
cle protein protection and preservation involves the
general support of protein homeostasis, the facili-
tation of three-dimensional protein folding into the
native molecular state and the protection of proteome
integrity. Therefore, progressive muscular dystrophy
is associated with drastic changes in chaperoning
molecules. Especially the class of small and relatively
muscle-specific chaperones might be useful for diag-
nostic and prognostic purposes. It is encouraging that
the molecular chaperone cvHsp has already been suc-
cessfully employed for the biochemical evaluation of
experimental exon skipping therapy [137]. A potential
disadvantage of heat shock proteins is their intra-
muscular location, but the proteomic profiling of the
secretome of mdx myotubes suggests that the released
chaperones HSP-5, HSP-8 and HSP90 may be suitable
biomarker candidates in biofluids [123].
Biotransformation enzymes
The continued detoxification of potentially harmful
substances, the biotransformation of xenobiotics and
the anti-oxidant protection are natural defense mecha-
nisms of muscle fibres and involve a variety of enzyme
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systems. It is therefore not surprising that free radical
production, oxidative stress and impaired biotransfor-
mation has been suggested to play an important role
in the molecular pathogenesis of dystrophinopathies
[185–187]. As discussed in detail by Tidball and
Wehling-Henricks [188], the loss of dystrophin and
concomitant disintegration of its associated glycopro-
tein complex causes the disruption of free radicals
production and this pathobiochemical alteration con-
tributes in a major way to muscular degeneration.
Possibly the disruption of cellular signaling mecha-
nisms or a drastic shift in free radicals production
is involved in cellular injury and resulting contrac-
tile weakness. The enzyme glutathione transferase is
a crucial catalyst in glutathione-dependent phase 2
biotransformation reactions [189]. An increased con-
centration of both glutathione transferase and catalase
was established to occur in the aged mdx heart as
judged by proteomic analysis [142].
These proteomic findings agree with elevated stress
levels in dystrophinopathies and the idea that intensi-
fied protein oxidation by highly reactive free radical
species causes cellular damage in both Duchenne
patients and the mdx mouse [186, 188]. Anti-oxidant
and biotransformation mechanisms appear to involve
both glutathione transferase and catalase in muscu-
lar dystrophy [189]. Since the experimental elevation
of catalase concentration was shown to improve mdx
muscle functions [190], the observed high expres-
sion of catalase in dystrophic fibres might represent a
major protective mechanism to decrease cellular injury
in muscular dystrophies. The proteomic identification
of significant changes in the concentration of glu-
tathione transferase and catalase might thus be useful
to establish especially a heart-specific biomarker sig-
nature of muscular dystrophy-related changes [170].
The general status of enzymes involved in anti-oxidant
responses and detoxification processes can then be
used for evaluating levels of biotransformation in dys-
trophic or pharmacologically treated muscles.
MUSCLE DISEASE DIAGNOSTICS AND
BIOMARKER DISCOVERY
Diagnosis of muscular dystrophy
Motor assessment plays an important role in the
evaluation of disease status in dystrophic patients
[191–194]. In addition to the review of clinical history
and physical examination, the conventional diagno-
sis of muscular dystrophies has heavily relied on
electro-diagnostic testing, enzyme assays for the detec-
tion of muscle-related serum activity, the genetic
evaluation of carriers and patients, the histological, his-
tochemical and immunochemical evaluation of muscle
biopsy specimens and the biochemical analyses of
disease-related protein changes by gel electrophoresis
and immunoblotting [71]. Since many of these rou-
tine tests are not very reliable, lack specificity with
respect to differentiating between distinct neuromus-
cular pathologies and are invasive, there is great scope
for the identification of superior diagnostic biomark-
ers of dystrophinopathies. A non-invasive alternative to
muscle biopsy procedures is represented by magnetic
resonance imaging and spectroscopy for the diagnosis
and monitoring of disease progression, and potentially
clinical outcome measures, in dystrophinopathies
[195–197]. The clinical value of this imaging technique
has been clearly demonstrated [198, 199] and a good
correlation exists between skeletal muscle histology, as
judged by the histochemical evaluation of muscle biop-
sies, and dystrophic changes observed by magnetic
resonance imaging technology [200]. However, MRI
scoring procedures require highly specialized equip-
ment, are labor-intensive and often too expensive for
routine screening programs. Hence, the development
of a simple and cost-effective biomarker assay of a min-
imally invasive or non-invasive nature would overcome
many of these financial and technical issues.
Proteomic biomarker discovery
With respect to developing dependable and
non-invasive tests, large-scale mass spectrometric
screening approaches are crucial for biomarker discov-
ery in the area of muscular dystrophy research. This
includes the development of reliable assay systems
for the evaluation of disease initiation, pathological
progression and the monitoring of therapeutic inter-
ventions. In addition, the proteomics-based discovery
of diagnostically conclusive biomarker signatures
of muscular diseases is crucial for an improved
understanding of the molecular pathogenesis of indi-
vidual disorders. Ideally, a panel of novel protein
biomarkers of dystrophinopathies will be useful for
initial disease diagnosis, prognostic evaluations and
the continued assessment of therapy efficacies. The
flowchart in Fig. 5 outlines the different classes of
biomarkers needed for the proper monitoring of dys-
trophinopathies. The changed abundance of specific
proteins, shifts in isoform expression patterns, mod-
ifications of protein-protein interactions, alterations
in post-translational modifications, the degradation of
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Fig. 5. Flowchart of the different classes of protein biomarkers that would be useful for the monitoring of dystrophinopathies. This includes
the altered concentration of specific muscle-associated protein species, potential shifts in protein isoform expression patterns, modifications
of protein-protein interactions, changes in post-translational modifications, the proteolytic degradation of proteins and/or the appearance of
muscle-derived proteins, protein fragments or peptides in body fluids.
distinct proteins and/or the appearance of muscle-
derived proteins, protein fragments or peptides in body
fluids might also provide new insights into pathologi-
cal mechanism of dystrophinopathies. Once significant
changes in protein concentration, protein constellation
and/or subcellular localization have been established
by biochemical and proteomic studies, dependable
biomarkers can then be tested for their overall diag-
nostic, prognostic or therapeutic potential. In general,
a protein biomarker should ideally be (i) easily assess-
able, (ii) very sensitive, (iii) diagnostically conclusive,
(iv) highly specific for subtypes of distinct disor-
ders, (v) informative in relation to individual stages
of disease progression and (vi) exhibit physicochem-
ical properties that make a particular protein species
suitable for the establishment of a meaningful and
cost-effective test system [64].
If the novel biomarker is an internal muscle-
associated protein, it should preferably be located
in a relatively restricted cellular compartment under
healthy conditions, exhibit an appropriate degree of
fibre type specificity within affected whole skeletal
muscles and show significant difference in density
levels, subcellular expression and/or molecular fea-
tures in dystrophic specimens versus normal muscle
samples. However, if the novel biomarker is a muscle-
derived protein that has leaked or been released
from contractile fibres, it should differ substantially
between its intracellular and extracellular presence
in undamaged versus dystrophic muscle. The degree
of the disease-related occurrence of muscle mark-
ers in body fluids should ideally correlate with the
onset, intensity and length of muscular damage. Both,
internal biomarkers requiring invasive biopsy proce-
dures or biofluid-associated muscle markers that can
be obtained by minimally invasive or non-invasive
methods, should be able to differentiate between acute
pathological insults and chronic tissue damage.
Circulating biomarkers for monitoring general
muscle damage
In the case of routine testing of Duchenne patients
and the evaluation of carrier detection rates, histori-
cally the most frequently used serum enzyme activity
has been creatine kinase [201]. In addition to serum
creatine kinase [202–208], other marker enzymes
are represented by carbonic anhydrase [209–212],
aldolase [213], adenylate kinase [214–216], lactate
dehydrogenase [206, 207, 213] and pyruvate kinase
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[206, 208, 217, 218]. Assay systems were used with
single enzyme activities or combinations of various
muscle-derived enzymes in patient serum [206–208,
211, 213]. Besides the examining of disease pro-
gression in dystrophic children, screening approaches
included fetal plasma [219, 220] and the blood analysis
of newborns [204, 205, 221], as well as a large number
of investigations into the evaluation of carrier status
[222–226]. The combined testing of several serum
markers has shown the potential of improved screen-
ing efficiency, such as the usage of creatine kinase,
myoglobin and hemopexin for identifying Duchenne
muscular dystrophy carriers [227]. Besides serum and
plasma, the testing of urine and saliva might also
be useful for future diagnostic testing [228–231].
Especially urine proteomics has great potential for dis-
covering new disease indicators that are suitable for the
establishment of simple and non-invasive assays [232].
The comparative profiling of the urine proteome has
already identified several urinary biomarkers of phys-
ical activity [233] and muscle wasting during cancer
cachexia [234].
Muscle-derived proteins as specific markers of
dystrophinopathies
In addition to the above outlined inherent compli-
cations of tissue proteomics, the future application of
diagnostic or prognostic biomarkers associated with
the muscle interior, as identified by proteomic profiling
of cell mixtures, would require the undesirable usage
of invasive methodology. Therefore proteomic screen-
ing programmes increasingly focus on the systematic
analysis of suitable body fluids for differential analy-
ses. In the future, the mining of the biofluid proteome
promises to play a key role in diagnostic biomarker
discovery in blood plasma, serum, urine and saliva
[235] and the identification of new therapeutic tar-
gets [236]. The underlying objective of searching for
biofluid-associated biomarkers is based on the assump-
tion that firstly damaged tissues, that exist in close
proximity to certain biological fluids, have a tendency
to actively release or passively leak proteins into their
external environment, and secondly that the overall
range and/or density of shed proteins relates to the
degree of cellular damage. This might lead to the iden-
tification of robust and unambiguous biomarkers of
high clinical value [237].
Since the identification and establishment of
biofluid-based biomarkers is essential for improved
diagnosis, enhanced approaches of risk stratification
and the optimum management of pathological devel-
opments, recently international efforts have intensified
and initiated the systematic screening of suitable body
fluids for muscle-derived proteins. However, in con-
trast to the large number of proteomic studies described
in above sections that have analysed muscle tissue
extracts or subcellular fractions [63], relatively few
mass spectrometric investigations that focus on leaked
or secreted proteins from dystrophic muscle tissues
have been published [118–123]. Serum and plasma,
examples of distal biofluids, are composed of compo-
nents originating from cells throughout the entire body,
including various hormones, enzymes, glycoproteins,
and growth factors. The choice of using serum versus
plasma under specific experimental conditions is both
acceptable. However, the HUPO committee and its
research partners recommend plasma as the preferred
specimen taken from blood, because it was found to
have less ex vivo degradation and much less variability
than the protease-rich process of clotting that is associ-
ated with serum processing [238, 239]. Many research
groups take the opportunity to examine both serum and
plasma in order to increase the overall coverage of the
blood proteome in their investigations [86, 240]. Iden-
tification of disease-specific biomarkers is challenging
in these samples given how substantially diluted
biomolecules are in a matrix containing components
derived from practically all tissues in the body [241].
Using ProteoMiner™ beads to reduce the high
dynamic range of the serum proteome from Duchenne
muscular dystrophy, Becker muscular dystrophy, Beth-
lem myopathy, Myasthenia gravis and control groups,
Martin et al. [122] found that fibronectin levels were
significantly increased in Duchenne patients as com-
pared to age-matched controls. In contrast, fibronectin
levels in patients suffering from Becker muscular dys-
trophy, Bethlem myopathy or Myasthenia gravis were
comparable to control levels. Fibronectin is a major
component of the extracellular matrix with normal
adult serum concentrations typically in the region of
220g/ml. Tissue fibrosis, a characteristic of pro-
gressive X-linked muscular dystrophy, is generally
considered to arise due to a failure of the normal
wound response to cease, a process dependent on
fibronectin in promoting cell adhesion and migration.
The highly progressive elevation of fibronectin lev-
els was also observed in longitudinal samples from
Duchenne patients [122]. Besides fibronectin, interest-
ing novel proteomic biomarker candidates of X-linked
muscular dystrophy are the coagulation factor XIIIa
and the matrix metalloproteinase MMP-9 [118–120].
It is important to note that no significant alterations of
the serum concentration of collagen and laminin were
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found in Duchenne patients, showing that measuring
these proteins is not useful for evaluating the extent of
fibrosis in dystrophinopathies [242].
Traditional biochemical analyses have previously
established elevated serum levels of tissue inhibitors
of metalloproteinase-1 and transforming growth factor
TGF-beta1 in Duchenne patients [243–246]. In addi-
tion, the proteomic screening of the secretome from
mdxmyotubes has demonstrated the release of a variety
of vesicle-related proteins [123]. The mass spec-
trometric analysis revealed that lysosome-associated
membrane protein 1 (LAMP1) containing vesicles
comprise myosin light chain MLC1 and cytoskeletal
proteins that are over-secreted in dystrophic myotubes
[123]. Since skeletal muscles are now considered a
secretory organ that releases a variety of myokines
[247], which are involved in signalling within the neu-
romuscular system and also other organs involved in
bioenergetic provision, the detailed analysis of the
muscle secretome promises opportunities both for
diagnostic and therapeutic purposes [248]. The future
screening of body liquids for muscle-derived peptides,
protein fragments or intact proteins should be able to
corroborate the already established proteomic findings
and hopefully identify additional suitable biomarker
candidates. An interesting new marker of general mus-
cle damage is the protein Xin [249]. If Xin-like proteins
would be identified as suitable markers of muscle dam-
age severity in dystrophinopathies, in conjunction with
released or leaked biomarkers, then the progressive
nature of muscular dystrophy could be monitored in
a more approachable fashion.
CONCLUSIONS
Biomarkers are measures of a biological state and
are used as an indicator to determine and evalu-
ate normal biological processes, pathogenic processes
or pharmacological responses to therapeutic regimes.
These biomarkers are produced either by the dis-
eased tissue itself or by other neighbouring tissues in
response to the presence of the disease or other associ-
ated conditions such as inflammation or the immune
response. Mass spectrometry-based proteomic sur-
veys of various muscles and body fluids, using both
gel electrophoresis and/or liquid chromatography for
large-scale protein separation, have identified a large
number of potential biomarker candidates for the
improved diagnostic evaluation of dystrophinopathies.
The subcellular localization and disease-related con-
centration changes of major biomarker candidates
of dystrophinopathies, as described in this review,
are summarized in the diagrammatic presentation of
Fig. 6. Listed are the major categories of protein fam-
ilies that have been identified by proteomics-based
screening approaches in conjunction with biochemi-
cal and cell biological verification analyses. Besides
the members of the dystrophin-glycoprotein com-
plex (dystrophin Dp427, dystroglycans, sarcoglycans,
dystrobrevins, syntrophins, sarcospan), the figure
includes proteins involved in (i) muscle contraction
and the cytoskeleton (myosin heavy chains, myosin
light chains, troponins, tropomyosin; auxiliary fila-
ment proteins, and the cytoskeletal proteins desmin,
vimentin and tubulin), (ii) excitation-contraction cou-
pling and ion homeostasis (calcium binding proteins,
ion channels), (iii) extracellular matrix (collagen),
(iv) cellular stress response (molecular chaperones
cvHsp, B-crystallin, Hsp70, Hsp90), (v) bioenergetic
and metabolic pathways (aldolase, isocitrate dehydro-
genase, adenylate kinase, creatine kinase) and (vi)
muscle-derived proteins in body fluids (fibronectin,
coagulation factor XIIIa, matrix metalloproteinase
MMP-9, transforming growth factor TGF1). Gen-
eral serum markers of muscle damage are represented
by creatine kinase, carbonic anhydrase and adeny-
late kinase, but these enzymes lack a high degree of
specificity. The unchanged expression levels of the
membrane cytoskeletal protein spectrin can be used
as a loading control in comparative studies of mus-
cle specimens. Laminin levels can be employed as
an unchanged protein in dystrophic skeletal muscle
preparations, but not for the analysis of cardiac tissues
since its abundance is greatly reduced in dystrophin-
deficient cardiac tissues.
In analogy to the dystrophic grmd dog, in the
future more detailed subproteomic studies might be
possible due to the development of larger animal
models of dystrophinopathies. Recently, the success-
ful generation of a pig model of X-linked muscular
dystrophy was reported using the targeted deletion
of exon 52 in the dystrophin gene of male pig
cells and the subsequent generation of severely dys-
trophic offspring by nuclear transfer [250]. The new
model of progressive Duchenne muscular dystro-
phy exhibits increased serum creatine kinase levels,
impaired mobility, contractile weakness and a dras-
tically reduced life span of pigs due to respiratory
impairment. Future proteomic studies of dystrophin-
deficient pigs may provide new insights into the
hierarchy of physiological derangements in severe
muscular dystrophy and provide sufficiently large
amounts of contractile tissue for detailed subproteomic
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Fig. 6. Overview of the subcellular localization and disease-related concentration changes of major biomarker candidates of dystrophinopathies.
This illustration summarizes the majority of protein families that have been identified by mass spectrometry-based proteomics as potential
biomarker candidates.
studies of the sarcolemma, mitochondria, sarcoplasmic
reticulum, transverse tubules and nuclei.
With respect to biomarker signatures on multiple
biomolecular levels including ideally DNA, RNA,
protein and metabolites, recent reports on muscle-
specific microRNAs and their suitability as minimally
invasive serum biomarkers for Duchenne muscular
dystrophy are encouraging [251–255]. The future com-
bination of parallel tests that determine significant
changes in muscle-associated proteomic biomarkers,
muscle-derived proteins or protein fragments in body
fluids, extracellular microRNAs and muscle metabo-
lites appears to be the most appropriate approach for the
comprehensive diagnostic, prognostic and therapeutic
evaluation of X-linked muscular dystrophy.
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